Form 4 for IGC IGC Pharma, Inc.
Accepted 2024-09-27 00:00:00 ET · period of report 2024-09-25 · accession 0001185185-24-000924 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-09-27 | 2024-09-25 | IGC | Moran James P | Dir | P - Purchase | $0.34 | +588.2K | 942.4K | +166% | +$200.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-25 | P | A | 588,235 | $0.34 | 942,402 | I See footnote | — | — | (F1) Represents shares of IGC Pharma, Inc. ("IGC") common stock purchased directly from IGC by Moran Global Strategies, Inc ("MGS"), a Virginia corporation that is owned by James Moran a director of IGC, subject to the terms and conditions set forth in the 2024 Share Purchase Agreement filed with the SEC on Form 8-K on September 25, 2024. The Reporting Person hereby disclaims beneficial ownership of all securities, except to the extent of any indirect pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |